Tag Archives: GlaxoSmithKline

Without An Rx, Some Pharmas Are Skittish

Lower margins and strong-arm direct-to-consumer campaigns are two of the primary barriers to selling nutraceuticals, according to a business school ‘war game’ conducted with the participation of Abbott, Danone (Dannon in the US), GSK and Nestlé. But the global nutraceuticals market – worth $80 billion in 2010, according to Frost & Sullivan – is expected […]
Posted in Advertising, Global, IP, Marketing, patient education, Regulatory, Strategy | Also tagged , , | 4 Comments

GSK Reps Trade Sales Targets for Sales Competencies

Last summer, GlaxoSmithKline announced plans to upend the pay structure for its US-based sales reps by removing incentives based on hard sales figures, or how many pills are sold. Instead of rewarding reps for the amount of product sold, GSK would begin rewarding reps for the quality of relationship they engender, the company said.
Posted in Marketing, Sales | Also tagged , | 1 Comment

Avandia, Pharma, and the New FDA

The Harvard prof who wrote the book on FDA (literally) deconstructs the decision on Avandia—and its future implications. GlaxoSmithKline’s diabetes drug Avandia became mired in such controversy regarding its safety in recent years that it was dubbed “another Vioxx”—exactly what the pharmaceutical industry had vowed never to produce. Two weeks ago, FDA’s decided to restrict […]
Posted in FDA, Regulatory, Safety | Also tagged , , , , | 2 Comments

Judgment Day for Avandia

Judgment Day has finally arrived for GSK’s Avandia. FDA’s Endocrinologic and Metabolic Drugs and Drug Safety and Risk Management Advisory Committees met July 13 and 14 to finally recommend, after months of deck-stacking against GSK, that the drug be severely restricted, if not outright pulled from the market. In the vote, 12 of 33 panelists […]
Posted in FDA, Regulatory | Also tagged , , , , , , | Leave a comment

Avandia on Trial

The mid-July FDA advisory committee meeting to decide the fate of GlaxoSmithKline’s Avandia (rosiglitazone) is widely viewed as a test case of how the agency’s new leadership will address controversial drugs with serious risks but confusing data. A request that GSK yank its diabetes blockbuster—three years after first being associated with an increased risk of […]
Posted in Legal | Also tagged , , , , , , | Leave a comment
  • Categories

  • Meta